Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: Potential role in neuropathology

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Sun, Ying ^a   Florer, Jane ^a   Mayhew, Christopher N ^a   Jia, Zhanfeng ^a,b   Zhao, Zhiying ^a,b   Xu, Kui ^a   Ran, Huimin ^a   Liou, Benjamin ^a   Zhang, Wujuan ^a   Setchell, Kenneth D R ^a   Gu, Jianguo ^a   Grabowski, Gregory A ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Synageva BioPharma Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDE; GLUCOSYLSPHINGOSINE; SPHINGOSINE DERIVATIVE; UNCLASSIFIED DRUG; ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; PSYCHOSINE; SPHINGOSYL BETA-GLUCOSIDE;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DEGLYCOSYLATION; DISEASE SEVERITY; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; FIBROBLAST; FLUOROMETRY; GAUCHER DISEASE; GENE FREQUENCY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; KARYOTYPING; LIPID ANALYSIS; MALE; MEMBRANE STEADY POTENTIAL; MORPHOLOGY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATCH CLAMP TECHNIQUE; PHENOTYPE; PLASMID; PLURIPOTENT STEM CELL; PROTEIN AGGREGATION; ANALOGS AND DERIVATIVES; CYTOLOGY; GENETICS; INDUCED PLURIPOTENT STEM CELL; MEMBRANE POTENTIAL; METABOLISM; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; PATHOLOGY; PHYSIOLOGY;

ALPHA-SYNUCLEIN; CELLS, CULTURED; FIBROBLASTS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MEMBRANE POTENTIALS; NEURAL STEM CELLS; NEUROGENESIS; NEURONS; PSYCHOSINE;

EID: 84926429926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118771     Document Type: Article

References (72)

1. Grabowski GA, Petsko GA, Kolodny EH (2010) Gaucher disease. In: Valle D, Beaudet A, Vogelstein B, Kinzler KW, Antonarakis SE et al., editors. The Online Metabolic and Molecular Bases of Inherited Diseases. New York: The McGraw-Hill Companies, Inc.
2. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008; 29: 567-583. doi: 10.1002/humu.20676 PMID: 18338393
3. Mignot C, Doummar D, Maire I, De Villemeur TB. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006; 28: 39-48. PMID: 16485335
4. Marshall J, McEachern KA, Chuang WL, Hutto E, Siegel CS, Shayman JA, et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis. 2010; 33: 281-289. doi: 10.1007/s10545-010-9072-z PMID: 20336375
5. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995; 122: 33-39. PMID: 7985893
6. Cabrera-Salazar MA, Deriso M, Bercury SD, Li L, Lydon JT, Weber W, et al. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One. 2012; 7: e43310. doi: 10.1371/journal.pone.0043310 PMID: 22912851
7. Nilsson O, Mansson JE, Hakansson G, Svennerholm L. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease. Biochim Biophys Acta. 1982; 712: 453-463. PMID: 7126619
8. Gornati R, Berra B, Montorfano G, Martini C, Ciana G, Ferrari P, et al. Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease. J Inherit Metab Dis. 2002; 25: 47-55. PMID: 11999980
9. Suomi WD, Agranoff BW. Lipids of the Spleen in Gaucher's Disease. J Lipid Res. 1965; 6: 211-219. PMID: 14328428
10. Pandey MK, Rani R, Zhang W, Setchell K, Grabowski GA. Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease. Mol Genet Metab. 2012; 106: 310-322. doi: 10.1016/j.ymgme.2012.04.020 PMID: 22595426
11. Liu J, Halene S, Yang M, Iqbal J, Yang R, Mehal WZ, et al. Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci U S A. 2012; 109: 10018-10023. doi: 10.1073/pnas.1200941109 PMID: 22665763
12. Kaye EM, Ullman MD, Wilson ER, Barranger JA. Type 2 and type 3 Gaucher disease: a morphological and biochemical study. Ann Neurol. 1986; 20: 223-230. PMID: 3752966
13. Beutler E, Grabowski GA (2001) Gaucher Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. eighth ed. New York: McGraw-Hill. pp. 3635-3668.
14. Nilsson O, Grabowski GA, Ludman MD, Desnick RJ, Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin Genet. 1985; 27: 443-450. PMID: 3924448
15. Orvisky E, Park JK, LaMarca ME, Ginns EI, Martin BM, Tayebi N, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab. 2002; 76: 262-270. PMID: 12208131
16. Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis. 2003; 14: 595-601. PMID: 14678774
17. Burrow TA, Sun Y, Prada CE, Bailey L, Zhang W, Brewer A, et al. CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11years of therapy: Clinical, histopathologic, and biochemical findings. Mol Genet Metab. 2014.
18. Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A. Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol. 1984; 65: 99-109. PMID: 6524300
19. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011; 146: 37-52. doi: 10.1016/j.cell.2011.06.001 PMID: 21700325
20. Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA. Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. 2011; 102: 436-447. doi: 10.1016/j.ymgme.2010.12.014 PMID: 21257328
21. Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet. 2014; 23: 3943-3957. doi: 10.1093/hmg/ddu105 PMID: 24599400
22. Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A. 2011; 108: 12101-12106. doi: 10.1073/pnas.1108197108 PMID: 21730160
23. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009; 361: 1651-1661. doi: 10.1056/NEJMoa0901281 PMID: 19846850
24. DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord. 2009; 24: 1571-1578. doi: 10.1002/mds.22538 PMID: 19425057
25. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol. 2011; 69: 940-953. doi: 10.1002/ana.22400 PMID: 21472771
26. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease - links to Parkinson's disease. Cell Metab. 2013; 17: 941-953. doi: 10.1016/j.cmet.2013.04.014 PMID: 23707074
27. Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int. 2013; 62: 1-7. doi: 10.1016/j.neuint.2012.10.010 PMID: 23099359
28. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-676. PMID: 16904174
29. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-872. PMID: 18035408
30. Panicker LM, Miller D, Park TS, Patel B, Azevedo JL, Awad O, et al. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A. 2012; 109: 18054-18059. doi: 10.1073/pnas.1207889109 PMID: 23071332
31. Tiscornia G, Lorenzo Vivas E, Matalonga L, Berniakovich I, Barragan Monasterio M, Eguizabal C, et al. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet. 2013; 22: 633-645. doi: 10.1093/hmg/dds471 PMID: 23118351
32. Panicker LM, Miller D, Awad O, Bose V, Lun Y, Park TS, et al. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells. 2014; 32: 2338-2349. doi: 10.1002/stem.1732 PMID: 24801745
33. Schondorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014; 5: 4028. doi: 10.1038/ncomms5028 PMID: 24905578
34. Wigderson M, Firon N, Horowitz Z, Wilder S, Frishberg Y, Reiner O, et al. Characterization of mutations in Gaucher patients by cDNA cloning. Am J Hum Genet. 1989; 44: 365-377. PMID: 2464926
35. Bergmann JE, Grabowski GA. Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. Am J Hum Genet. 1989; 44: 741-750. PMID: 2495719
36. Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics. 1989; 4: 87-96. PMID: 2914709
37. Theophilus B, Latham T, Grabowski GA, Smith FI. Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am J Hum Genet. 1989; 45: 212-225. PMID: 2502917
38. Tsuji S, Choudary PV, Martin BM, Stubblefield BK, Mayor JA, Barranger JA, et al. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med. 1987; 316: 570-575. PMID: 2880291
39. Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI. Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci U S A. 1988; 85: 2349-2352. PMID: 3353383
40. Watson CL, Mahe MM, Munera J, Howell JC, Sundaram N, Poling HM, et al. An in vivo model of human small intestine using pluripotent stem cells. Nat Med. 2014; 20: 1310-1314. doi: 10.1038/nm.3737 PMID: 25326803
41. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282: 1145-1147. PMID: 9804556
42. Warlich E, Kuehle J, Cantz T, Brugman MH, Maetzig T, Galla M, et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther. 2011; 19: 782-789. doi: 10.1038/mt.2010.314 PMID: 21285961
43. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011; 8: 409-412. doi: 10.1038/nmeth.1591 PMID: 21460823
44. Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, Topf N, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci U S A. 2004; 101: 12543-12548. PMID: 15310843
45. Sun Y, Quinn B, Xu YH, Leonova T, Witte DP, Grabowski GA. Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model. J Lipid Res. 2006; 47: 2161-2170. PMID: 16861620
46. Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol. 2003; 163: 2093-2101. PMID: 14578207
47. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, et al. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010; 19: 1088-1097. doi: 10.1093/hmg/ddp580 PMID: 20047948
48. Sun Y, Liou B, Xu YH, Quinn B, Zhang WJ, Hamler R, et al. Ex Vivo and in Vivo Effects of Isofagomine on Acid beta-Glucosidase Variants and Substrate Levels in Gaucher Disease. Journal of Biological Chemistry. 2012; 287: 4275-4287. doi: 10.1074/jbc.M111.280016 PMID: 22167193
49. Sun Y, Zamzow M, Ran H, Zhang W, Quinn B, Barnes S, et al. Tissue-specific effects of saposin A and saposin B on glycosphingolipid degradation in mutant mice. Hum Mol Genet. 2013; 22: 2435-2450. doi: 10.1093/hmg/ddt096 PMID: 23446636
50. Antonchuk J. Formation of embryoid bodies from human pluripotent stem cells using AggreWell plates. Methods Mol Biol. 2013; 946: 523-533. doi: 10.1007/978-1-62703-128-8-32 PMID: 23179853
51. Beutler E, Kuhl W. Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with type I, type II, and type III Gaucher disease. Proc Natl Acad Sci U S A. 1986; 83: 7472-7474. PMID: 3463977
52. Budde T, White JA. The voltage-dependent conductances of rat neocortical layer I neurons. Eur J Neurosci. 1998; 10: 2309-2321. PMID: 9749759
53. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. Cell. 2008; 134: 877-886. doi: 10.1016/j.cell.2008.07.041 PMID: 18691744
54. Grafe M, Thomas C, Schneider J, Katz B, Wiley C. Infantile Gaucher's disease: a case with neuronal storage. Ann Neurol. 1988; 23: 300-303. PMID: 2837134
55. Cervos-Navarro J, Zimmer C. Light microscopic and ultrastructural study on CNS lesions in infantile Gaucher's disease. Clin Neuropathol. 1990; 9: 310-313. PMID: 2286024
56. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004; 82: 192-207. PMID: 15234332
57. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem. 1982; 39: 709-718. PMID: 7097276
58. Yamaguchi Y, Sasagasako N, Goto I, Kobayashi T. The synthetic pathway for glucosylsphingosine in cultured fibroblasts. J Biochem. 1994; 116: 704-710. PMID: 7852294
59. Ogawa Y, Tanaka M, Tanabe M, Suzuki T, Togawa T, Fukushige T, et al. Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease. PLoS One. 2013; 8: e55856. doi: 10.1371/journal.pone.0055856 PMID: 23383290
60. Kiskinis E, Sandoe J, Williams LA, Boulting GL, Moccia R, Wainger BJ, et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014; 14: 781-795. doi: 10.1016/j.stem.2014.03.004 PMID: 24704492
61. Maor G, Rencus-Lazar S, Filocamo M, Steller H, Segal D, Horowitz M. Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J Rare Dis. 2013; 8: 140. doi: 10.1186/1750-1172-8-140 PMID: 24020503
62. Suzuki T, Shimoda M, Ito K, Hanai S, Aizawa H, Kato T, et al. Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS One. 2013; 8: e69147. doi: 10.1371/journal.pone.0069147 PMID: 23936319
63. Wang F, Segatori L. Remodeling the proteostasis network to rescue glucocerebrosidase variants by inhibiting ER-associated degradation and enhancing ER folding. PLoS One. 2013; 8: e61418. doi: 10.1371/journal.pone.0061418 PMID: 23620750
64. Sun Y, Zhang W, Xu YH, Quinn B, Dasgupta N, Liou B, et al. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models-implications for Gaucher disease. PLoS One. 2013; 8: e57560. doi: 10.1371/journal.pone.0057560 PMID: 23520473
65. Nilsson O, Hakansson G, Dreborg S, Groth CG, Svennerholm L. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clin Genet. 1982; 22: 274-279. PMID: 7151312
66. Park H, Haynes CA, Nairn AV, Kulik M, Dalton S, Moremen K, et al. Transcript profiling and lipidomic analysis of ceramide subspecies in mouse embryonic stem cells and embryoid bodies. J Lipid Res. 2010; 51: 480-489. doi: 10.1194/jlr.M000984 PMID: 19786568
67. Jakobsson A, Westerberg R, Jacobsson A. Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog Lipid Res. 2006; 45: 237-249. PMID: 16564093
68. Ben-David O, Futerman AH. The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. Neuromolecular Med. 2010; 12: 341-350. doi: 10.1007/s12017-010-8114-x PMID: 20502986
69. Eyal N, Wilder S, Horowitz M. Prevalent and rare mutations among Gaucher patients. Gene. 1990; 96: 277-283. PMID: 2269438
70. Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat. 2000; 15: 181-188. PMID: 10649495
71. Hong CM, Ohashi T, Yu XJ, Weiler S, Barranger JA. Sequence of two alleles responsible for Gaucher disease. DNA Cell Biol. 1990; 9: 233-241. PMID: 1972019
72. Beutler E, Gelbart T, Kuhl W, Sorge J, West C. Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. Proc Natl Acad Sci U S A. 1991; 88: 10544-10547. PMID: 1961718